‘慢’而‘小’，这种癌症很特别 慢性淋巴细胞白血病/小淋巴细胞淋巴瘤Chronic lymphocytic leukaemia/small lymphocytic lymphoma，CLL/SLL）在最新版（第五版）WHO淋巴组织肿瘤分类中归属为肿瘤前期和肿瘤性小淋巴细胞增殖（Pre-neoplastic and neoplastic small lymphocytic proliferations），主要发生在中老年人群，90%以上...
慢性淋巴细胞白血病(chronic lymphocytic leukemia，CLL)的治疗模式正在发生历史性的变化。从传统免疫化疗到非化疗，从单药不确定性治疗到新药确定性治疗。CLL的治疗模式和策略经历了巨大变革。CLL属于B细胞来源的慢性淋巴细胞增生性疾病，该病的高发年龄为65-70岁。我国CLL发病率低于西方国家，但随着人口老龄化与常规体检...
慢性淋巴细胞白血病(CLL) 慢性淋巴细胞白血病是一种成熟B淋巴细胞克隆增殖性肿瘤,临床表现外周血淋巴细胞增多、肝脾及淋巴结肿大,并累及淋巴系统以外其他器官,晚期可表现为骨髓衰竭。慢性淋巴细胞白血病(chronic lymphocytic leukemia,CLL)与小淋巴...
概述 慢性淋巴细胞白血病(Chronic lymphocytic leukemia,CLL)是一种淋巴细胞克隆性增殖疾病,表现为淋巴细胞在骨髓、淋巴结、血液、脾脏、肝脏及其他器官聚集。95%以上的CLL为B细胞的克隆性增殖(即B-CLL),即形似成熟而有缺陷的肿瘤性淋巴细胞大量增生,淋巴细胞的寿...
The FDA granted a fast track designation to BGB-16673, a novel drug used to treat chronic lymphocytic leukemia and small lymphocytic lymphoma. The Anxieties I Face Before Chemo Treatments for CLL Chester Freeman August 19th 2024 As I visit the cancer center for chemotherapy to treat my CLL, I...
Chronic lymphocytic leukemia (CLL) remains the most prevalent form of leukemia in the western world, with no cure to date. Ongoing and essential research into this heterogeneous disease has led to a number of new treatment options becoming available to CLL patients in the last decade. This ...
01、慢性淋巴细胞白血 chroniclymphocytic leukemia,CLL)/ 小淋巴细胞淋巴瘤 (small lymphocytic lymphoma,SLL)是一种成熟B细胞克隆增殖性肿瘤,以形态学成熟的小淋巴细胞在外周血、骨髓、脾脏、淋巴结及其他器官聚集为特征的血液系统恶性疾病,是一种惰性造血组织恶性肿瘤。
RITUXANis a prescription medicine used to treat adults with: Non-Hodgkin’s Lymphoma (NHL): alone or with other chemotherapy medicines. Chronic Lymphocytic Leukemia (CLL): with the chemotherapy medicines fludarabine and cyclophosphamide. It is not known if RITUXAN is safe and effective in children ...
[1]NCCN Guidelines Version 1.2023 Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma. *本材料由阿斯利康支持,仅供医疗卫生专业人士参考。 审批编号:CN-113868 有效期至: 2023-7-26 *"医学界"力求所发表内容专业、可靠,但不对内容的准确性做出承诺;请相关各方在采用或以此作为决策依据时另行核查。
[4]Hillmen P,Eichhorst B,Brown JR,et al.First interim analysis of ALPINE study:results of a phase 3 randomized study of zanubrutinib vs ibrutinib in patients with relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma[abstract].EHA Virtual Congress;2021:Abstract LB1900. ...